Nothing Special   »   [go: up one dir, main page]

BR9910749A - Composições e vacinas imunogênicas combinadas para meningites b e c e método de induzir uma resposta imune por administração da mesma - Google Patents

Composições e vacinas imunogênicas combinadas para meningites b e c e método de induzir uma resposta imune por administração da mesma

Info

Publication number
BR9910749A
BR9910749A BR9910749-0A BR9910749A BR9910749A BR 9910749 A BR9910749 A BR 9910749A BR 9910749 A BR9910749 A BR 9910749A BR 9910749 A BR9910749 A BR 9910749A
Authority
BR
Brazil
Prior art keywords
meningitis
vaccines
inducing
administering
immune response
Prior art date
Application number
BR9910749-0A
Other languages
English (en)
Inventor
Dan M Granoff
Ingeborg S Aaberge
Bjorn Haneberg
Johan Holst
Howard Raff
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of BR9910749A publication Critical patent/BR9910749A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/832—Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Fats And Perfumes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Beans For Foods Or Fodder (AREA)

Abstract

<B>COMPOSIçõES E VACINAS IMUNOGêNICAS COMBINADAS PARA MENINGITES B E C E MéTODO DE INDUZIR UMA RESPOSTA IMUNE POR ADMINISTRAçãO DA MESMA<D>. A presente invenção é direcionada a uma vacina combinada para Neisseria meningitidis compreendendo proteínas de membrana externa de sorogrupo B e oligossacarídeos de sorogrupo C, e seu uso para a prevenção ou tratamento da doença.
BR9910749-0A 1998-05-29 1999-05-28 Composições e vacinas imunogênicas combinadas para meningites b e c e método de induzir uma resposta imune por administração da mesma BR9910749A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8735198P 1998-05-29 1998-05-29
US10644698P 1998-10-30 1998-10-30
PCT/US1999/011977 WO1999061053A1 (en) 1998-05-29 1999-05-28 Combination meningitidis b/c vaccines

Publications (1)

Publication Number Publication Date
BR9910749A true BR9910749A (pt) 2001-02-13

Family

ID=26776879

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9910749-0A BR9910749A (pt) 1998-05-29 1999-05-28 Composições e vacinas imunogênicas combinadas para meningites b e c e método de induzir uma resposta imune por administração da mesma

Country Status (15)

Country Link
US (1) US8007815B1 (pt)
EP (2) EP1079857B1 (pt)
JP (2) JP5074644B2 (pt)
AT (1) ATE346609T1 (pt)
AU (2) AU761495B2 (pt)
BR (1) BR9910749A (pt)
CA (1) CA2332963C (pt)
CY (1) CY1107550T1 (pt)
DE (1) DE69934225T2 (pt)
DK (1) DK1079857T3 (pt)
ES (2) ES2278446T3 (pt)
HK (1) HK1034460A1 (pt)
NZ (1) NZ508771A (pt)
PT (2) PT1741443E (pt)
WO (1) WO1999061053A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998012332A1 (en) 1996-09-17 1998-03-26 Chiron Corporation Compositions and methods for treating intracellular diseases
WO1999061053A1 (en) 1998-05-29 1999-12-02 Chiron Corporation Combination meningitidis b/c vaccines
WO2000071725A2 (en) 1999-05-19 2000-11-30 Chiron S.P.A. Combination neisserial compositions
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
EP2281570A3 (en) * 2000-01-17 2012-05-09 Novartis Vaccines and Diagnostics S.r.l. Outer membrane vesicle (OMV) vaccine comprising n. meningitidis serogroup B outer membrane proteins
KR20030024811A (ko) 2000-07-27 2003-03-26 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 나이세리아 메닌지티디스에 의하여 유발되는 질병에 대한광범위하게 유효한 보호를 위한 백신
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
ES2615362T3 (es) 2001-07-27 2017-06-06 Glaxosmithkline Biologicals Sa Adhesinas de meningococos
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
SI1961426T1 (sl) 2003-10-02 2011-10-28 Novartis Ag Kombinirana cepiva proti meningitisu
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
CN101107007B (zh) 2005-01-27 2011-08-17 奥克兰儿童医院及研究中心 对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
SI2200642T1 (sl) * 2007-10-19 2012-06-29 Novartis Ag Formulacije meningokoknega cepiva
CA2772104A1 (en) * 2009-08-27 2011-03-03 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
CA2808975C (en) 2010-08-23 2018-10-30 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
ES2759484T3 (es) 2010-09-10 2020-05-11 Glaxosmithkline Biologicals Sa Meningococo que sobreexpresa NadA y/o NHBA y vesículas de la membrana externa derivadas del mismo
ES2864635T3 (es) 2010-09-10 2021-10-14 Wyeth Llc Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
GB201015132D0 (en) * 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
KR101716557B1 (ko) 2012-03-09 2017-03-14 화이자 인코포레이티드 수막염균 조성물 및 이의 사용 방법
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
JP6324961B2 (ja) 2012-09-06 2018-05-16 ノバルティス アーゲー 血清群ｂ髄膜炎菌とｄ／ｔ／ｐとの組み合わせワクチン
EP2897635A1 (en) 2012-09-18 2015-07-29 Novartis AG Outer membrane vesicles
ES2685894T3 (es) 2013-03-08 2018-10-15 Pfizer Inc. Polipéptidos de fusión inmunogénicos
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
MX2017010705A (es) 2015-02-19 2017-12-04 Pfizer Composiciones de neisseria meningitidis y metodos de la misma.
KR102567845B1 (ko) 2017-01-31 2023-08-17 화이자 인코포레이티드 네이세리아 메닌기티디스 조성물 및 그의 방법

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
EP0449958B9 (en) * 1988-12-19 2003-05-28 American Cyanamid Company Meningococcal class 1 outer-membrane protein vaccine
US7118757B1 (en) * 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
EP0624376B1 (en) 1993-05-13 2000-03-15 American Cyanamid Company Preparation and uses of LOS-depleted outer membrane proteins of gram-negative cocci
WO1995029662A2 (en) 1994-04-20 1995-11-09 U.S. Department Of The Army Vaccine against gram-negative bacterial infections
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
US6476201B1 (en) * 1995-09-18 2002-11-05 Id Biomedical Corporation Of Quebec Methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines
DE19601754A1 (de) * 1996-01-19 1997-07-24 Hoechst Ag Dictyocaulus viviparus Antigen zur Diagnose des Lungenwurmbefalls und zur Vakzinierung
US5846735A (en) * 1996-04-18 1998-12-08 University Of Iowa Research Foundation Hepatitis C virus Fc-binding function
DK0939647T4 (da) * 1996-08-27 2006-10-23 Novartis Vaccines & Diagnostic Neisseria Meningitidis-serogruppe B-glycokonjugat og fremgangsmåde til anvendelse deraf
US6558677B2 (en) * 1996-10-15 2003-05-06 Wendell D. Zollinger Vaccine against gram negative bacteria
US6413520B1 (en) * 1997-06-24 2002-07-02 Chiron Corporation Methods of immunizing adults using anti-meningococcal vaccine compositions
AU748973B2 (en) * 1997-07-17 2002-06-13 Baxter Healthcare Sa Immunogenic conjugates comprising a group B meningococcal porin and an H. influenzae polysaccharide
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
WO1999061053A1 (en) 1998-05-29 1999-12-02 Chiron Corporation Combination meningitidis b/c vaccines
WO2001034642A2 (en) 1999-11-12 2001-05-17 University Of Iowa Research Foundation Control of neisserial membrane synthesis
KR20030024811A (ko) 2000-07-27 2003-03-26 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 나이세리아 메닌지티디스에 의하여 유발되는 질병에 대한광범위하게 유효한 보호를 위한 백신
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US10272147B2 (en) 2003-01-30 2019-04-30 Glaxosmithkline Biologicals S.A. Injectable vaccines against multiple meningococcal serogroups
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
SI1961426T1 (sl) 2003-10-02 2011-10-28 Novartis Ag Kombinirana cepiva proti meningitisu

Also Published As

Publication number Publication date
EP2796148A3 (en) 2015-02-25
CA2332963C (en) 2013-07-23
PT1741443E (pt) 2014-07-31
ES2485940T3 (es) 2014-08-14
EP1079857A1 (en) 2001-03-07
ES2278446T3 (es) 2007-08-01
DK1079857T3 (da) 2007-01-29
HK1034460A1 (en) 2001-10-26
DE69934225D1 (de) 2007-01-11
JP2002516292A (ja) 2002-06-04
AU2003244518A1 (en) 2003-09-25
EP1079857B1 (en) 2006-11-29
NZ508771A (en) 2003-08-29
ATE346609T1 (de) 2006-12-15
AU4221599A (en) 1999-12-13
AU761495B2 (en) 2003-06-05
JP5074644B2 (ja) 2012-11-14
CA2332963A1 (en) 1999-12-02
US8007815B1 (en) 2011-08-30
DE69934225T2 (de) 2007-09-27
WO1999061053A1 (en) 1999-12-02
CY1107550T1 (el) 2013-03-13
JP2009292851A (ja) 2009-12-17
EP2796148A2 (en) 2014-10-29
PT1079857E (pt) 2007-02-28

Similar Documents

Publication Publication Date Title
BR9910749A (pt) Composições e vacinas imunogênicas combinadas para meningites b e c e método de induzir uma resposta imune por administração da mesma
Austrian Prevention of pneumococcal infection by immunization with capsular polysaccharides of Streptococcus pneumoniae: current status of polyvalent vaccines
LU92262I2 (fr) Vaccin méningococcique groupe B (ADNr, composant, adsorbé) et ses dérivés pharmaceutiquement acceptables (BEXSERO)
BR9815255A (pt) Toxina de botulismo modificada, vacina oralcontra o botulismo, vacina oral contra umantìgeno selecionado e método para ministraroralmente um agente terapêutico a um animal
LU91778I2 (fr) Menveo - vaccin méningococcique des groupes A,C, W135 et Y conjugué.
BRPI0407877A (pt) conjugado de peptìdeo-proteìna, vacina para a prevenção ou melhora da infecção pelo vìrus influenza, e, método para induzir um resposta imune em um paciente
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
NO980883D0 (no) Forbindelser og fremgangsmåter for immunterapi og diagnose av tuberkulose
DE60045721D1 (de) Streptococcus pneumoniae Proteine und Impfstoffe
CA2022420A1 (en) Escherichia coli vaccine
PT854924E (pt) Antigenios de leishmania para uso na terapia e diagnostico da leishmaniose
CY1106092T1 (el) Χρηση του μακρου μοριου της πεντραξινης ρτχ3 για τη θepαπεια ασθενειων που προκαλουνται απο μια μεταβαλλομενη ενepγοποιηση του αυξητικου παραγοντα fgf-2
DE60331412D1 (de) Hiv-vakzine und anwendungsverfahren
CY1108178T1 (el) Βακτηριο που προκαλει νοσο των πουλερικων και εμβολιο προερχομενο εξ&#39; αυτου
DK1112747T3 (da) Salmonellavaccine, som ikke inducerer antistoffer mod flagellin eller flageller
EP1741443A3 (en) Combination meningitidis B/C vaccines
BRPI0414073A (pt) método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
DE60042489D1 (de) Impfstoff gegen neisseria infektion
FR2809960B1 (fr) Composition adjuvante de la reponse immunitaire comprenant la proteine fha ou un fragment de la proteine fha sous forme libre, et composition immunogene ou vaccinale contenant une telle composition adjuvante
CY1113746T1 (el) Εμβολιο που περιλαμβανει ανοσοενισχυτικο γαλακτωμα ελαιου σε υδωρ
Van den Bosch Escherichia coli vaccine

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US)

Free format text: ALTERADO DE: CHIRON CORPORATION

B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: A REQUERENTE DEVERA APRESENTAR OS DOCUMENTOS DE CESSAO REFERENTES AS PRIORIDADES US 60/087.351 DE 29/05/1998 E US 60/106.446 DE 30/10/1998 REIVINDICADAS NO PI9910749-0.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O C/C 13, 24 E 25 DA LPI.

B15V Prolongation of time limit allowed

Free format text: DEVOLVIDO O PRAZO DE 15 (QUINZE) DIAS, NOS TERMOS DO ARTIGO 221 PARAGRAFO 2O DA LPI E DA RESOLUCAO116/04.

B12B Appeal against refusal [chapter 12.2 patent gazette]